Beginning with its exatecan ADC, STRO-004, aimed at Tissue Factor, the biotechnology company situated in South San Francisco ...

with early signs of efficacy that the partners say warrant further development of the ADC in this setting.

has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the development and commercialization of Antibody-Drug Conjugates (ADC).

Callio Therapeutics has raised $187m in Series A financing round for achieving clinical proof-of-concept for HER2-targeted ...

LigaChem Biosciences is now positioned to take a significant step forward in ADC development for solid tumor patients. DAAN Biotherapeutics has successfully established a proprietary pipeline for ...

By leveraging DAAN Biotherapeutics' next-generation antibody technology, built upon its exceptional target discovery and antibody development capabilities, LigaChem Biosciences is now positioned to ...